Education

University of California, Berkeley, B.A., 01/2006, Molecular and Cell Biology
New York University School of Medicine, M.D., 01/2015, Medicine
New York University Sackler Institute, Ph.D., 01/2013, Developmental Genetics
University of California, San Francisco, Resident, 01/2018, Anatomic Pathology
University of California, San Francisco, Fellow, 01/2018, Surgical Pathology

Honors & Awards

  • 2002
    Regents' Scholarship, University of California, Berkeley
  • 2005
    Biology Fellows Program Semester Research Grant (Mentor: John Coates), University of California, Berkeley
  • 2007
    Summer Scholarship for Medical Students (Mentor: Joel Ernst), Infectious Diseases Society of America
  • 2008
    Award for Academic Excellence and Achievement, American Society of Clinical Pathology
  • 2011
    3rd place poster prize, 18th International C. elegans Meeting, Genetics Society of America
  • 2016
    Chief Resident, Department of Pathology, San Francisco VA Medical Center
  • 2016
    Pathologist in Training Travel Award, 92nd Annual AANP Meeting, American Association of Neuropathologists
  • 2017
    Chief Resident, Department of Pathology, San Francisco General Hospital
  • 2017
    Pathologist in Training Travel Award, USCAP Annual Meeting, United States and Canadian Academy of Pathology
  • 2017
    Visiting scholar. Genitourinary pathology. Mentor: Victor Reuter. 1 month., Memorial Sloan Kettering Cancer Center
  • 2018
    Visiting scholar. Genitourinary pathology. Mentor Jesse McKenney. 1 month., Cleveland Clinic

Selected Publications

  1. Cheng AV, Wu DJ, Friedman LA, Chan E, Williamson SR, Galea LA, Sangoi AR. MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms. Virchows Arch. 2025 Jan 25.  View on PubMed
  2. Mubeen A, Pacheco R, Akgul M, Williamson SR, Collins K, Chan E, Sangoi AR. Gamna-Gandy bodies in renal neoplasms: A multi-institutional clinicopathologic study of 350 consecutive nephrectomies. Ann Diagn Pathol. 2025 Jan 14; 75:152440.  View on PubMed
  3. Kayraklioglu N, Stohr BA, Chan E. Clinicopathologic and Molecular Characterization of High-Risk Human Papillomavirus-Positive Carcinomas of the Urinary Tract. Arch Pathol Lab Med. 2025 Jan 01; 149(1):30-38.  View on PubMed
  4. Bernhardt M, Weinhold L, Bremmer F, Chan E, Cheng L, Collins K, Downes M, Greenland N, Hommerding O, Iczkowski KA, Jufe L, Kreft T, van Leenders G, Oxley J, Perry-Keene J, Reis H, Schmid M, Tsuzuki T, Wobker S, Wiliamson SR, Kweldam C, Kristiansen G. Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance. Histopathology. 2024 Nov 28.  View on PubMed
  5. Bhattacharya I, Stacke K, Chan E, Lee JH, Tse JR, Liang T, Brooks JD, Sonn GA, Rusu M. Aggressiveness classification of clear cell renal cell carcinoma using registration-independent radiology-pathology correlation learning. Med Phys. 2025 Jan; 52(1):300-320.  View on PubMed
  6. Tanaka K, Kayraklioglu N, Chan E, Ding CC, Vohra P. Utility of The Paris System for Reporting Urinary Cytology in patients with HPV-positive urinary tract carcinoma. Cancer Cytopathol. 2025 Jan; 133(1):e22914.  View on PubMed
  7. Kayraklioglu N, Chan E, Bastian B, Long SR. Primary Melanoma of the Urinary Bladder: Clinical, Histopathologic, and Comprehensive Molecular Analysis of a Rare Tumor. Int J Surg Pathol. 2024 Oct 03; 10668969241283486.  View on PubMed
  8. Sangoi AR, Al-Obaidy KI, Akgul M, Mehra R, Chan E, Williamson SR. Cowper Glands Identified in Prostate and Urethral Specimens: A Comprehensive Immunohistochemical Characterization and Potential Diagnostic Pitfall. Int J Surg Pathol. 2024 Aug 21; 10668969241268375.  View on PubMed
  9. Pinard A, Chen C, Van Ziffle J, Simko JP, Stohr BA, Chan E. Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions. Ann Diagn Pathol. 2024 Dec; 73:152370.  View on PubMed
  10. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097.  View on PubMed
  11. Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology. 2024 Oct; 85(4):598-613.  View on PubMed
  12. Chan GJ, Stohr BA, Osunkoya AO, Croom NA, Cho SJ, Balassanian R, Charu V, Bean GR, Chan E. Wilms Tumor: An Unexpected Diagnosis in Adult Patients. Arch Pathol Lab Med. 2024 Jun 01; 148(6):722-727.  View on PubMed
  13. Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. Prostate. 2024 Aug; 84(11):1076-1085.  View on PubMed
  14. Potterveld SK, Williamson SR, Al-Obaidy KI, Akgul M, Chan E, Giannico GA, Sangoi AR. GATA3 Expression in Prostatic Adenosquamous Carcinoma: A Potential Diagnostic Pitfall. Int J Surg Pathol. 2025 Feb; 33(1):85-91.  View on PubMed
  15. Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2024 03 01; 30(5):1009-1021.  View on PubMed
  16. Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024; 14(4):1344-1360.  View on PubMed
  17. de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024 Apr; 84(5):426-440.  View on PubMed
  18. Williams EA, Ravindranathan A, Gupta R, Stevers NO, Suwala AK, Hong C, Kim S, Yuan JB, Wu J, Barreto J, Lucas CG, Chan E, Pekmezci M, LeBoit PE, Mully T, Perry A, Bollen A, Van Ziffle J, Devine WP, Reddy AT, Gupta N, Basnet KM, Macaulay RJB, Malafronte P, Lee H, Yong WH, Williams KJ, Juratli TA, Mata DA, Huang RSP, Hiemenz MC, Pavlick DC, Frampton GM, Janovitz T, Ross JS, Chang SM, Berger MS, Jacques L, Song JS, Costello JF, Solomon DA. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. Neuro Oncol. 2023 12 08; 25(12):2221-2236.  View on PubMed
  19. Greenland NY, Cowan JE, Stohr BA, Simko JP, Carroll PR, Chan E. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer. Histopathology. 2024 Mar; 84(4):614-623.  View on PubMed
  20. Chaiton M, Thorburn R, Chan E, Copeland I, Luphuyong C, Feng P. Evaluating Web-Based Care for Mental Health and Substance Use Issues for Lesbian, Gay, Bisexual, Transgender, Queer, Questioning, and 2-Spirit Youths in the Context of the COVID-19 Pandemic: Community-Based Participatory Research Study. J Med Internet Res. 2023 11 17; 25:e44292.  View on PubMed

Go to UCSF Profiles, powered by CTSI